20388-87-8

Usage

Uses

Used in Pharmaceutical Industry:
Beta-methyl-phenethylaminhydrochloride is used as a pharmaceutical intermediate for the development of various medications. Its agonistic properties on the human trace amine-associated receptor 1 make it a valuable compound in the research and development of potential therapeutic agents.
Used in Forensic Science:
In the field of forensic science, BMPEA is utilized for the analysis and identification of novel doping substances. Its classification as a novel doping substance aids in the detection and prevention of its misuse in sports and other competitive environments.
Used in Research and Development:
Beta-methyl-phenethylaminhydrochloride serves as a crucial compound in research and development, particularly in the study of the human trace amine-associated receptor 1 and its role in various physiological processes. This research can lead to the discovery of new therapeutic targets and the development of innovative treatments for a range of conditions.

InChI:InChI=1/C9H13N.ClH/c1-8(7-10)9-5-3-2-4-6-9;/h2-6,8H,7,10H2,1H3;1H

Upstream product

• 1823-91-2 1-phenylethyl cyanide 
• 1634-04-4 tert-butyl methyl ether 
• 582-22-9 2-phenylpropylamine 
• 31731-86-9 2-phenylpropylmagnesium bromide 

Downstream Products

• 582-22-9 2-phenylpropylamine 
• 1016057-29-6 N-(2-phenylpropyl)-4-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

Two-dimensional perovskite chiral ferromagnets

Magnetic molecular materials with a chiral configuration are attractive candidates for sensing, information storage, and spintronics. Herein, we report the first example of two-dimensional hybrid perovskite chiral ferromagnets, (R-MPEA)2CuCl4 and (S-MPEA)2CuCl4. These two compounds exhibit strong oppositely signed circular dichroism signals and clear ferromagnetic behaviors. Magnetic measurements revealed high saturation magnetization up to 12.5 emu g-1. The coexistence of strong chirality and ferromagnetism enabled successful study on their magneto-chiral dichroism spectra. These findings demonstrate a new materials platform for future magneto-optical and spintronic applications, providing insights to the structure-property correlation of chiral ferromagnetic perovskite.

TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Tetrahydroisoquinoline compounds of formula (I), and compositions containing them, for the treatment of acute, inflammatory and neurophatic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neurophatic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintened pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

AMPA RECEPTOR POTENTIATORS

The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

Synthesis of primary amines by the electrophilic amination of Grignard reagents with 1,3-dioxolan-2-one O-sulfonyloxime

(Chemical equation presented) Primary amines are prepared by the electrophilic amination of Grignard reagents with 4,4,5,5-tetramethyl-1,3- dioxolan-2-one O-phenylsulfonyloxime and the acidic hydrolysis of the resulting imines.

Process for preparing biphenyl compounds

The present invention relates to a process for the preparation of a biphenyl compound comprising combining a phenyl boronic acid derivative with an halobenzene derivative in the presence of a suitable additive in a suitable organic solvent with a suitable catalyst and a suitable base.

Combination therapy for treatment of depression

The present invention provides a method for treating depression, comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is a suitable AMPA receptor potentiator.

Sulfonamide derivatives

The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders. 1

Heterocyclic sulfonamide derivatives

The present invention provides certain heterocyclic sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.